News-Medical.Net November 25, 2024
A research group at LMU University Hospital has investigated how Alzheimer’s disease can be diagnosed more reliably in the future.
Soon they will be authorized in Germany: the first drugs against Alzheimer’s disease that are intended to slow down the progression of the condition. On November 14, 2024, the EMA granted approval for Lecanemab in the European Union. The drugs attack so-called amyloid plaques in the brain. But how can we reliably and cost-effectively diagnose the presence of amyloid plaques in patients who show up at memory clinics with slight cognitive impairment or mild dementia – that is, the target group for the drugs?
A new study by doctors at LMU University Hospital furnishes answers which could be incorporated into...
Today's Sponsors
Today's Sponsor